🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Florida
Clinical trial register · United States · industry-sponsored

Clinical Trials in Florida, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9126 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 26 Sep 2026, 03:16 UTC
9126
Studies in scope
industry-sponsored, all four open statuses
4955
Recruiting now
open to new participants
2200
Lead sponsors
across recruiting studies
Top states
California 5303 Florida 4408 Illinois 2477 Georgia 2354 Arizona 2235
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca173 Eli Lilly and Company150 Merck Sharp & Dohme LLC116 AbbVie112 Novartis Pharmaceuticals108
State
California5303 Florida4408 Illinois2477 Georgia2354 Arizona2235
All 51 states
Target enrolment
to

Trials with a site in Florida

4408 of 9126 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Active, closed
A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)
NCT05738486Alzheimer's Disease, Dementia, Brain Diseases, Central Nervous System Diseases
DrugsDonanemab·Dexamethasone
Eli Lilly and Company
Phase 3
1,175
Arizona, California, Florida, Georgia, Massachusetts, Michigan, New Jersey, Rhode Island
2023-02-28
Active, closed
Efficacy and Safety of ATX01 in Adult Patients With CIPN (Chemotherapy-induced Peripheral Neuropathy)
NCT05593614Chemotherapy-induced Peripheral Neuropathy
AlgoTherapeutix
Phase 2
276
Florida, Kansas, Maryland, New York, Texas
2023-02-28
Recruiting
R-3750 in Patients With Mild to Moderate Ulcerative Colitis
NCT05666960Ulcerative Colitis Chronic Mild, Ulcerative Colitis Chronic Moderate, Ulcerative Colitis Chronic, Ulcerative Colitis
Rise Therapeutics LLC
Phase 1
36
California, Florida, Minnesota
2023-02-27
Recruiting
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
NCT05723198Areata Alopecia, Alopecia, Hypotrichosis, Hair Diseases
DrugBaricitinib
Eli Lilly and Company
Phase 3
595
Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Indiana
2023-02-27
Active, closed
DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)
NCT05566795Low-grade Glioma, Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma, Pediatric Low-grade Glioma
DrugTovorafenib
Day One Biopharmaceuticals, Inc.
Phase 3
418
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2023-02-27
Active, closed
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)
NCT05548127Breast Cancer
DrugsARV-471·Abemaciclib
Pfizer
Phase 1/2
37
California, Florida, Illinois, Missouri, Texas, Washington
2023-02-23
Active, closed
Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy
NCT06018558Geographic Atrophy
Ocugen
Phase 1/2
60
Arizona, Florida, Indiana, Mississippi, Missouri, New Jersey, North Carolina, Pennsylvania
2023-02-23
Recruiting
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
NCT05651932Multiple Myeloma, Myeloma, Myeloma Multiple
DrugsMezigdomide·Carfilzomib·Pomalidomide
K36 Therapeutics, Inc.
Phase 1
165
California, Florida, Georgia, Massachusetts, Minnesota, New Jersey, New York, North Carolina
2023-02-22
Recruiting
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
NCT05503797Cancer Harboring BRAF Alterations, HGG, LGG, Solid Tumors
Fore Biotherapeutics
Phase 2
254
California, Connecticut, Florida, Maryland, Massachusetts, Minnesota, Missouri, Nebraska
2023-02-21
Active, closed
Study With Various Immunotherapy Treatments in Participants With Lung Cancer
NCT05676931Advanced Non-Small Cell Lung Cancer
DrugsQuemliclustat·Domvanalimab·Zimberelimab·Paclitaxel
Gilead Sciences
Phase 2
400
Alabama, California, Florida, Illinois, Louisiana, Michigan, Virginia, Washington
2023-02-21
Active, closed
Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Children 4-7 Years of Age
NCT05741476Allergy, Peanut
DBV Technologies
Phase 3
600
Alabama, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia
2023-02-21
Active, closed
A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Antiretroviral Therapy (ART) (MK-8591A-051)
NCT05631093HIV-1 Infection
DrugDOR/ISL
Merck Sharp & Dohme LLC
Phase 3
553
California, District of Columbia, Florida, Georgia, New Jersey, Pennsylvania, Texas
2023-02-20
By invitation
Safety Study of Tenapanor for the Treatment of Pediatric Patients (6 to Less Than 18 Years Old) With IBS-C
NCT05905926Irritable Bowel Syndrome With Constipation (IBS-C)
DrugTenapanor
Ardelyx
Phase 3
150
Alabama, California, Florida, Illinois, Indiana, Maine, Minnesota, Nebraska
2023-02-17
Active, closed
A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052)
NCT05630755HIV-1 Infection
DrugsBIC/FTC/TAF·DOR/ISL
Merck Sharp & Dohme LLC
Phase 3
514
Arizona, California, District of Columbia, Florida, Georgia, Massachusetts, Michigan, Missouri
2023-02-17
Active, closed
A Trial to Investigate Different Doses of Lonapegsomatropin Compared to Somatropin in Individuals With Turner Syndrome
NCT05690386Turner Syndrome
Ascendis Pharma Endocrinology Division A/S
Phase 2
48
California, Colorado, Florida, Georgia, Idaho, Illinois, Massachusetts, Minnesota
2023-02-15
Active, closed
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
NCT05702034Ischemic Stroke; Ischemic Attack, Transient
DrugMilvexian
Janssen Research & Development, LLC
Phase 3
12,523
Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2023-02-15
Active, closed
A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)
NCT05722015Metastatic Non-small Cell Lung Cancer
DrugsPembrolizumab Formulated with Berahyaluronidase Alfa·Filgrastim·Taxol·Nab-paclitaxel
Merck Sharp & Dohme LLC
Phase 3
377
Arizona, Florida, Illinois, Indiana, Kentucky, Mississippi, Missouri
2023-02-14
Active, closed
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
NCT05607004Breast Neoplasms, Invasive Breast Cancer, Estrogen-receptor-positive Breast Cancer, HER2-negative Breast Cancer
DrugGoserelin
Atossa Therapeutics, Inc.
Phase 2
87
Arizona, California, Florida, Illinois, Kentucky, Michigan, Minnesota, Missouri
2023-02-14
Recruiting
A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
NCT05667142Primary Generalized Tonic-Clonic Seizures
DrugAzetukalner
Xenon Pharmaceuticals Inc.
Phase 3
160
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Hawaii
2023-02-14
Active, closed
Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD
NCT05711940Treatment Resistant Depression
DrugPsilocybin
COMPASS Pathways
Phase 3
572
Arizona, California, Florida, Georgia, Illinois, Massachusetts, Michigan, Minnesota
2023-02-14
Active, closed
A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A
NCT05685238Haemophilia A, Haemophilia A With Inhibitors
Novo Nordisk A/S
Phase 3
451
California, Colorado, Florida, Georgia, Illinois, Indiana, Iowa, Michigan
2023-02-13
Recruiting
Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Pediatric ORION-16, ORION-13, ORION-20, or ORION-19 Studies
NCT05682378Heterozygous or Homozygous Familial Hypercholesterolemia
DrugInclisiran
Novartis Pharmaceuticals
Phase 3
195
Florida, New York, Ohio, Pennsylvania, Utah
2023-02-10
Active, closed
Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma
NCT05605899High-risk Large B-cell Lymphoma (LBCL)
DrugsAxicabtagene Ciloleucel·Vincristine·Doxorubicin·Prednisone
Kite, A Gilead Company
Phase 3
300
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Iowa
2023-02-10
Recruiting
A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
NCT05519475Metabolic Dysfunction-Associated SteatoHepatitis (MASH)
Regeneron Pharmaceuticals
Phase 2
120
Arizona, California, Colorado, Florida, Indiana, Louisiana, Maryland, Mississippi
2023-02-09
Active, closed
A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
NCT05578976Diffuse Large B-Cell Lymphoma
DrugsEpcoritamab·Vincristine·Doxorubicin·Prednisone
Genmab
Phase 3
900
Arizona, Arkansas, California, Colorado, Florida, Hawaii, Illinois, Indiana
2023-02-08
Recruiting
Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant Epilepsy
NCT05518578Epilepsy, Seizures, Epileptic
DrugSPN-817
Supernus Pharmaceuticals, Inc.
Phase 2
60
Florida
2023-02-07
Recruiting
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
NCT05722418Relapsed/Refractory Multiple Myeloma
Caribou Biosciences, Inc.
Phase 1
50
Alabama, Colorado, Florida, Kentucky, New Jersey, New York, North Carolina, Ohio
2023-02-06
Active, closed
Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)
NCT05609968Carcinoma, Non-Small-Cell Lung
DrugsSacituzumab Govitecan·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
614
Alabama, California, Florida, Georgia, Louisiana, Michigan, Minnesota, New York
2023-02-06
By invitation
A Study to Follow Patients With Adult Growth Hormone Deficiency (AGHD) Treated With Sogroya® for Long Term Safety Information
NCT05718570Adult Growth Hormone Deficiency
DrugSomapacitan
Novo Nordisk A/S
Observational
400
Arizona, California, Colorado, Florida, Georgia, Illinois, Maryland, Massachusetts
2023-02-03
Recruiting
HP-211 Safety and Proof of Concept Dose Ranging Study in Patients With Type 2 Diabetes
NCT07546929Type 2 Diabetes
Housey Healthcare ULC
Phase 2
300
California, Florida, Georgia, Kansas, Louisiana, Michigan, Nebraska, Nevada
2023-02-03
Active, closed
GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease
NCT05686551Huntington Disease
Hoffmann-La Roche
Phase 2
301
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Illinois, Iowa
2023-02-03
Active, closed
Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)
NCT05653349Primary Immune Thrombocytopenia (ITP)
DrugIanalumab
Novartis Pharmaceuticals
Phase 3
226
Arizona, California, Colorado, Florida, Illinois, Indiana, Maryland, Massachusetts
2023-02-03
Recruiting
Pilot/Pivotal Study of DBS+Rehab After Stroke
NCT05701280Stroke, Upper Extremity Paresis
Enspire DBS Therapy, Inc.
Not applicable
202
Arizona, Florida, Maryland, Massachusetts, Minnesota, New York, Ohio, Pennsylvania
2023-02-03
Recruiting
Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers
NCT05395624Amyotrophic Lateral Sclerosis (ALS), Parkinson Disease (PD), Alzheimer Disease (AD), Multiple Sclerosis (MS)
Ashvattha Therapeutics, Inc.
Phase 1/2
65
California, Florida
2023-02-02
Recruiting
The Impact of MeMed BV® on Management of Patients With Suspected Lower Respiratory Tract Infections (LRTI) in the Emergency Department (ED) and Urgent Care Center (UCC) ("JUPITER" TRIAL)
NCT05762302Lower Respiratory Tract Infection
MeMed Diagnostics Ltd.
Not applicable
1,316
Florida, Kansas, New York, Pennsylvania, South Carolina, Texas, Wisconsin
2023-01-31
Active, closed
Open-Label Extension Study of DCCR in Patients With Prader-Willi Syndrome
NCT05701774Prader-Willi Syndrome
Soleno Therapeutics, Inc.
Phase 3
83
California, Florida, Georgia, Indiana, Maryland, Massachusetts, Michigan, Minnesota
2023-01-31
Active, closed
A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia
NCT05520567Acute Myeloid Leukemia (AML), FLT3-mutated Acute Myeloid Leukemia
DrugsGilteritinib·Venetoclax
Astellas Pharma Global Development, Inc.
Phase 1/2
70
California, Colorado, Florida, Illinois, Maryland, New York, North Carolina, Ohio
2023-01-31
Active, closed
A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder
NCT05733546Major Depressive Disorder
DrugPsilocybin
COMPASS Pathways
Phase 2
102
California, Florida, Maryland, Massachusetts, Texas
2023-01-30
Recruiting
MYLUNG Consortium Part 3: Observational Study
NCT05885698Carcinoma, Non-Small-Cell Lung
US Oncology Research
Observational
7,500
Alabama, Arizona, Colorado, Florida, Illinois, Maryland, Minnesota, New York
2023-01-30
Active, closed
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma
NCT05748600Eosinophilic Asthma, Asthma; Eosinophilic, Asthma Attack
DrugDexpramipexole Dihydrochloride
Areteia Therapeutics
Phase 3
600
Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana, Kentucky
2023-01-30
Active, closed
A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer
NCT05609370Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer
DrugsFluoropyrimidine·Bevacizumab biosimilar·Bevacizumab·Tislelizumab
BeiGene
Phase 1/2
113
Alaska, Arizona, California, Florida, Indiana, Kentucky, Louisiana, Missouri
2023-01-29
Recruiting
A Real World Study of eCoin for Urgency Urinary Incontinence: Post Approval Evaluation (RECIPE)
NCT05685433Overactive Bladder, Urge Incontinence, Incontinence, Urinary, Urinary Urge Incontinence
Valencia Technologies Corporation
Not applicable
200
Alabama, Arkansas, California, Florida, Georgia, Illinois, Iowa, Kansas
2023-01-26
Active, closed
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer
NCT05563220Breast Cancer, Metastatic Breast Cancer
DrugsElacestrant·Capivasertib·Alpelisib·Everolimus
Stemline Therapeutics, Inc.
Phase 1/2
435
Alabama, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Illinois
2023-01-24
Recruiting
ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)
NCT05580562H3 K27M, Glioma
Jazz Pharmaceuticals
Phase 3
510
Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Hawaii, Illinois
2023-01-23
Active, closed
Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis
NCT05739435Plaque Psoriasis
DrugEnvudeucitinib
Alumis Inc
Phase 2
165
Alabama, Arizona, Arkansas, California, Florida, Georgia, Illinois, Indiana
2023-01-17
Recruiting
To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation
NCT05541822Advanced Solid Tumors
DrugLazertinib
Abion Inc
Phase 2
178
Florida, Michigan, Texas
2023-01-17
Active, closed
ABTECT - Maintenance
NCT05535946Ulcerative Colitis
Abivax S.A.
Phase 3
1,116
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2023-01-16
Active, closed
A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery
NCT05608291Melanoma
DrugsFianlimab·Cemiplimab·Pembrolizumab
Regeneron Pharmaceuticals
Phase 3
1,564
California, Colorado, Florida, Illinois, Massachusetts, Michigan, New Jersey, New York
2023-01-16
Recruiting
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
NCT05614739Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral Neoplasms
DrugsVepugratinib·Digoxin·Rosuvastatin·Enfortumab Vedotin
Eli Lilly and Company
Phase 1
677
Arizona, California, Florida, Georgia, Illinois, Indiana, Louisiana, Maryland
2023-01-12
Active, closed
A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)
NCT05617677Systemic Lupus Erythematosus
DrugDeucravacitinib
Bristol-Myers Squibb
Phase 3
516
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois
2023-01-12
Active, closed
A Study to Investigate the Efficacy and Safety of Dupilumab Therapy Compared With Placebo in Participants Aged ≥18 Years With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype (LIBERTY-UC SUCCEED (Study in UC for Clinical Efficacy Evaluation of Dupilumab))
NCT05731128Colitis Ulcerative
DrugDupilumab
Sanofi
Phase 2
68
California, Florida, Georgia, New Jersey, New York, North Carolina, Pennsylvania, Texas
2023-01-12
Active, closed
A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus
NCT05620407Systemic Lupus Erythematosus
DrugDeucravacitinib
Bristol-Myers Squibb
Phase 3
513
California, Florida, Georgia, Illinois, Louisiana, Massachusetts, Michigan, Minnesota
2023-01-12
Active, closed
First in Human Study of IMGN151 in Recurrent Gynaecological Cancers
NCT05527184Endometrial Cancer, High Grade Serous Adenocarcinoma of Ovary, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
DrugIMGN151
AbbVie
Phase 1
256
Alabama, California, Colorado, Florida, Illinois, Massachusetts, Michigan, Mississippi
2023-01-11
Active, closed
Real-world Clinical Outcomes of the MITRIS RESILIA Mitral Valve
NCT05526560Mitral Stenosis, Mitral Valve Insufficiency
Edwards Lifesciences
Observational
504
California, Florida, Georgia, Indiana, Michigan, Minnesota, Missouri, New York
2023-01-11
By invitation
Tornier HRS (Humeral Reconstruction System) Study (REVIVE)
NCT05500066Rheumatoid Arthritis, Osteoarthritis Shoulder, Fractures Humerus, Avascular Necrosis
Stryker Trauma and Extremities
Observational
110
Colorado, Florida, Kentucky
2023-01-11
Recruiting
Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
NCT05573126Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer
DrugsElacestrant·Exemestane·Everolimus·Abemaciclib
Ellipses Pharma
Phase 1/2
95
Connecticut, Florida, Massachusetts, Michigan, Tennessee, Texas, Virginia
2023-01-11
Active, closed
A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease
NCT05668013Crohn Disease, Colitis, Ulcerative
Teva Branded Pharmaceutical Products R&D LLC
Phase 2
247
California, Florida, Illinois, Indiana, Kansas, Kentucky, Missouri, Nevada
2023-01-11
Active, closed
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
NCT05555732Metastatic Non Small Cell Lung Cancer
DrugsDatopotamab Deruxtecan·Pemetrexed·Cisplatin·Carboplatin
Daiichi Sankyo
Phase 3
1,170
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Maryland
2023-01-11
Recruiting
Alleviant ALLAY-HF Study
NCT05685303Heart Failure
Alleviant Medical, Inc.
Not applicable
700
Arizona, California, Connecticut, Florida, Georgia, Illinois, Indiana, Kentucky
2023-01-10
Active, closed
A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)
NCT05552976Relapsed or Refractory Multiple Myeloma
DrugsMezigdomide·Carfilzomib·Dexamethasone
Bristol-Myers Squibb
Phase 3
606
Alabama, California, Florida, Georgia, Idaho, Maryland, Massachusetts, Minnesota
2023-01-10
Active, closed
A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)
NCT05506943Biliary Tract Cancer, Cholangiocarcinoma, Gall Bladder Cancer, Ampullary Cancer
DrugPaclitaxel
Compass Therapeutics
Phase 2/3
168
Arizona, California, Colorado, Florida, Illinois, Louisiana, Maryland, Massachusetts
2023-01-09
Active, closed
BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma
NCT05322590Metastatic Colorectal Carcinoma, Neuropathy
Bexion Pharmaceuticals, Inc.
Phase 1/2
195
Alabama, California, Florida, Iowa, Kentucky, Louisiana, New York, Ohio
2023-01-09
Active, closed
A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease
NCT05662241IgG4 Related Disease
DrugObexelimab
Zenas BioPharma (USA), LLC
Phase 3
194
California, Florida, Georgia, Massachusetts, Michigan
2023-01-09
Recruiting
DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis
NCT05701917Venous Thromboembolism, Deep Venous Thrombosis, Post-Thrombotic Syndrome
Inari Medical
Not applicable
300
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Indiana
2023-01-06
Recruiting
Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare
NCT05658575Acute Gout Flare, Gout Attack, Gout Flare, Gouty Arthritis
Olatec Therapeutics, Inc.
Phase 2/3
300
Alabama, Arizona, California, Florida, Georgia, Illinois, Kentucky, Michigan
2023-01-06
Recruiting
Endurant Stent Graft System vs Excluder Endoprothesis: ADVANCE Trial
NCT05378347Abdominal Aortic Aneurysm, Abdominal Aortic Aneurysm >= 5.5 Centimeters in Male (Disorder), Abdominal Aortic Aneurysm >= 5.0 Centimeters in Female (Disorder)
Medtronic Cardiovascular
Not applicable
600
California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois, Kansas
2023-01-05
Active, closed
Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric Diffuse Intrinsic Pontine Gliomas (DIPG)
NCT05630209Brain Tumor
DrugDoxorubicin
InSightec
Phase 1/2
10
District of Columbia, Florida, Texas
2023-01-04
Active, closed
A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors
NCT05653882Solid Tumor, Non Small Cell Lung Cancer, Melanoma, Squamous Cell Carcinoma of Head and Neck
DrugsEtakafusp alfa·Pembrolizumab
Asher Biotherapeutics, Inc.
Phase 1
552
California, Connecticut, Florida, Illinois, Massachusetts, Michigan, Missouri, New Jersey
2023-01-04
Active, closed
AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)
NCT05693142Duchenne Muscular Dystrophy
REGENXBIO Inc.
Phase 2/3
65
Arkansas, California, Colorado, Florida, Georgia, Illinois, Iowa, Kansas
2023-01-04
Recruiting
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
NCT05592626Advanced Solid Tumors, Genital Neoplasm, Female, Urogenital Neoplasms, Lung Neoplasm
DrugSTAR0602
Marengo Therapeutics, Inc.
Phase 1/2
366
California, Florida, Kansas, Maryland, Massachusetts, Michigan, Ohio, Tennessee
2023-01-04
Active, closed
Phase 2b Study of GSK4532990 in Adults With NASH
NCT05583344Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease
DrugGSK4532990
GlaxoSmithKline
Phase 2
284
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Indiana
2023-01-02
Active, closed
Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma
NCT05678673Non-Clear Cell Renal Cell Carcinoma
DrugsZanzalintinib·Nivolumab
Exelixis
Phase 3
317
California, Colorado, Florida, New York, Ohio, Texas
2023-01-01
By invitation
A Long-Term Follow-Up Study in Severe Hemophilia A Subjects Who Received BMN 270 in a Prior BioMarin Clinical Trial (270-401)
NCT05768386Hemophilia A
BioMarin Pharmaceutical
Observational
172
California, Colorado, Florida, Kentucky, Michigan, Missouri, Ohio, Pennsylvania
2023-01-01
Active, closed
Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer
NCT05654532Breast Cancer
Accutar Biotechnology Inc
Phase 1
100
Colorado, Florida, Maryland, Tennessee, Texas, Virginia, Washington
2022-12-29
Active, closed
A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
NCT05595642Chronic Obstructive Pulmonary Disease (COPD)
DrugAstegolimab
Hoffmann-La Roche
Phase 3
1,290
Alabama, Arizona, California, Florida, Georgia, Indiana, Kentucky, Louisiana
2022-12-29
Active, closed
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
NCT05687266NSCLC
DrugsDatopotamab Deruxtecan·Dato-DXd·Durvalumab·Pemetrexed
AstraZeneca
Phase 3
1,350
Arizona, Arkansas, California, Colorado, Florida, Illinois, Indiana, Iowa
2022-12-29
Active, closed
A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis.
NCT05627362Primary Sclerosing Cholangitis
DrugElafibranor
Ipsen
Phase 2
68
California, Colorado, Connecticut, Florida, Georgia, Louisiana, Maryland, Massachusetts
2022-12-29
By invitation
Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study
NCT05645536Breast Cancer
DrugsTOL2506·Tamoxifen·Anastrozole·Exemestane
Tolmar Inc.
Phase 3
250
California, Florida, Kentucky, Maryland, New York, North Carolina, Pennsylvania, Tennessee
2022-12-28
Recruiting
Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively
NCT05568719Hemophilia A, Hemophilia B
Pfizer
Phase 3
173
California, Florida, Mississippi, New York, Pennsylvania, Washington
2022-12-28
Active, closed
Safety and Effectiveness of the Genio® bilAteral Stimulation for Treatment of Complete Concentric CollapsE and OSA.
NCT05592002Sleep Apnea, Obstructive
Nyxoah S.A.
Not applicable
124
Colorado, Florida, Indiana, Iowa, Kansas, Massachusetts, New York, Pennsylvania
2022-12-28
Recruiting
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
NCT05712200Atrial Fibrillation (AF)
DrugAbelacimab
Anthos Therapeutics, Inc.
Phase 3
2,500
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois
2022-12-27
Recruiting
A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
NCT05648214Healthy Volunteers, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Regeneron Pharmaceuticals
Phase 1/2
172
California, Florida, Louisiana, Texas
2022-12-27
Recruiting
A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
NCT05645107Hypogammaglobulinemia, Bacterial Infections, B-cell Chronic Lymphocytic Leukemia, Multiple Myleoma
DrugXembify
Grifols Therapeutics LLC
Phase 3
386
California, Florida, Maryland, North Carolina, Ohio, South Carolina
2022-12-26
Active, closed
Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)
NCT05531526Alzheimer Disease
AriBio Co., Ltd.
Phase 3
1,535
Arizona, California, Colorado, Florida, Georgia, Illinois, Louisiana, Massachusetts
2022-12-23
Recruiting
PROMISE III: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia
NCT05313165Critical Limb Ischemia, Chronic Limb-Threatening Ischemia, Peripheral Arterial Disease
LimFlow, Inc.
Not applicable
100
California, Connecticut, Florida, Illinois, Massachusetts, Missouri, New Hampshire, New Jersey
2022-12-22
Active, closed
ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer
NCT05446298Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
DrugsONC-392·Pembrolizumab
OncoC4, Inc.
Phase 2
58
Arizona, Connecticut, Florida, Illinois, Indiana, Kentucky, Louisiana, Minnesota
2022-12-22
Recruiting
Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies
NCT05488548Castrate Resistant Prostate Cancer, NUT Carcinoma, Chronic Myelomonocytic Leukemia, Myelofibrosis
Epigenetix, Inc.
Phase 1
75
Arizona, Florida, Massachusetts, Minnesota, Texas, Washington
2022-12-21
Recruiting
PyloPlus Urea Breath Test System Post Therapy Efficacy Confirmation Study
NCT05681689Helicobacter Pylori Infection, Post-Treatment, Efficacy
ARJ Medical, Inc.
Phase 3
77
Florida, New Jersey
2022-12-21
By invitation
Impella ECP Study (ECP Study) and Impella ECP Continued Access Protocol
NCT05334784High-Risk Percutaneous Coronary Intervention
Abiomed Inc.
Not applicable
856
Arizona, Arkansas, California, Florida, Georgia, Louisiana, Massachusetts, Michigan
2022-12-20
Active, closed
A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer
NCT05653752Non Small Cell Lung Cancer, Breast Cancer
DrugYL202
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1
80
Florida, Michigan, Texas, Virginia, Washington
2022-12-20
Recruiting
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
NCT05549297Advanced Melanoma
DrugTebentafusp
Immunocore Ltd
Phase 3
540
Arizona, Florida, Georgia, Kansas, Kentucky, Massachusetts, Minnesota, Missouri
2022-12-19
Active, closed
A Medical Device to Treat Wide-Neck Brain Aneurysms
NCT05550571Ruptured Cerebral Aneurysm
EndoStream Medical
Not applicable
45
Florida, New York
2022-12-17
Recruiting
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
NCT05232916Breast Cancer
Greenwich LifeSciences, Inc.
Phase 3
2,250
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2022-12-16
Recruiting
A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis
NCT05287126Ulcerative Colitis
DrugEtrasimod
Pfizer
Phase 2
36
Arkansas, California, Florida, Illinois, Massachusetts, Michigan, Ohio, Texas
2022-12-16
Active, closed
A Study of Daratumumab
NCT05438043Multiple Myeloma
DrugsCarfilzomib·Pomalidomide·Daratumumab·Dexamethasone
Janssen Research & Development, LLC
Phase 3
213
Florida, Georgia, Michigan, Missouri, New York, Texas
2022-12-15
Active, closed
A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma
NCT05675449Multiple Myeloma
DrugsElranatamab·Carfilzomib
Pfizer
Phase 1
59
Arkansas, California, Florida, Georgia, Iowa, Maryland, Massachusetts, New Jersey
2022-12-14
Recruiting
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
NCT05768932Advanced Solid Tumor, TNBC - Triple-Negative Breast Cancer, Gastric Cancer, Leukemia Acute Myeloid Leukemia (AML)
SillaJen, Inc.
Phase 1
260
Connecticut, Florida, Georgia, Michigan, New York, Oregon, Texas
2022-12-14
Active, closed
Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial
NCT05581303Atherosclerotic Cardiovascular Disease
DrugOlpasiran
Amgen
Phase 3
7,297
Alabama, Alaska, Arizona, California, Colorado, Connecticut, District of Columbia, Florida
2022-12-14
Active, closed
A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)
NCT05469737Myelodysplastic Syndromes
DrugVenetoclax
Bristol-Myers Squibb
Phase 2/3
230
Florida, New York, Pennsylvania, Texas, Virginia
2022-12-14
Recruiting
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
NCT05624450Viral Lung Infection and Acute Respiratory Failure
DrugTozorakimab
AstraZeneca
Phase 3
3,527
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Idaho
2022-12-13
Rows per page Showing 3001–3100 of 4408
Previous 29 30 31 32 33 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 September 2026. https://priyalifescience.com/clinical-trials-usa/state/florida?page=31

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,126 studies in total at the last sync on 26 Sep 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 4,408 of those studies with a site in Florida.

How many clinical trials are recruiting in Florida?

2,367 of the 4,408 studies on this page are recruiting new participants as of the 26 Sep 2026, 03:16 UTC sync. A further 102 have not yet opened recruitment, 1,830 are active but closed to new participants, and 109 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.